Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai's Phase III trial - Study 305 - evaluating perampanel has demonstrated that perampanel, 8mg and 12mg reduces median seizure frequency in comparison to placebo among patients having partial-onset seizures while receiving treatment with one to three other epilepsy drugs.
Subscribe to our email newsletter
Perampanel is an orally administered, highly selective non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist discovered and being developed by Eisai.
In Study 305, the response rates (defined as 50% or greater reduction in seizure frequency) were 14.7% for placebo, 33.3% for 8mg and 33.9% for 12mg.
The results of the trial demonstrated that perampanel 8mg once-daily reduced median seizure frequency by 30.5% and perampanel 12mg once-daily reduced median seizure frequency by 17.6% vs placebo (9.7 percent) among patients receiving treatment with one to three other epilepsy drugs.
Eisai Neuroscience Product Creation Unit president Lynn Kramer said this third Phase III study demonstrated the statistical and clinical efficacy of perampanel for reducing partial-onset seizures among epilepsy patients.